Background：Mirvetuximab soravtansine IMGN853 is a first-in-class ADC comprising a folate receptor alpha FRα-binding antibody, cleavable linker, and the maytansinoid payload DM4, a potent tubulin-targeting agent to kill the targeted cancer cells.
Alternative Names：M9346A, IMGN853, M9346A-sulfo-SPDB-DM4,
